Author

F. Porrot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 11 Approach:experimental assay· 10 Organism:human· 8 Assay:proteomics· 5 Organism:virus· 3 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

O. Schwartz· 11 shared C. Planchais· 9 shared D. Planas· 9 shared H. Mouquet· 9 shared T. Bruel· 9 shared F. Guivel-Benhassine· 7 shared I. Staropoli· 7 shared L. Hocqueloux· 7 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersMicrobiology

O. Schwartz

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

D. Planas, I. Staropoli, V. Michel, F. Lemoine, F. Donati, M. Prot, F. Porrot, F. G. Benhassine, B. Jeyarajah, A. Brisebarre, O. Dehan, L. Avon, W. Bolland, M. Hubert, J. Buchreiser, , O. Schwartz

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

bioRxiv · Nov 20, 2023 · PreprintMicrobiology

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1

W. Bolland, V. Michel, D. Planas, M. Hubert, F. Guivel-Benhassine, F. Porrot, I. Staropoli, M. N'Debi, C. Rodriguez, S. Fourati, M. Prot, C. Planchais, L. Hocqueloux, E. Simon-Loriere, H. Mouquet, , J. Buchrieser

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

bioRxiv · Sep 6, 2023Microbiology

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

D. Planas, T. Bruel, I. Staropoli, F. Guivel-Benhassine, F. Porrot, P. Maes, L. Grzelak, M. Prot, S. Mougari, C. Planchais, J. Puech, M. Saliba, R. Sahraoui, F. Femy, N. Morel, , O. Schwartz

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

bioRxiv · Nov 17, 2022Microbiology

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies

L. Grzelak, F. Roesch, A. Vaysse, A. Biton, F. Porrot, P.-H. Commere, C. Planchais, H. Mouquet, M. Vignuzzi, T. Bruel, O. Schwartz

This study identifies IRF8 as a regulator of CD20 expression and anti-CD20 antibody efficacy through CRISPR screening and functional validation in B cells.

bioRxiv · Jun 9, 2022Immunology

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

N. Saunders, D. Planas, W. H. Bolland, C. Rodriguez, S. Fourati, J. Buchrieser, C. Planchais, M. Prot, I. Staropoli, F. Guivel-Benhassine, F. Porrot, D. Veyer, H. Pere, N. Robillard, M. Saliba, , O. Schwartz

This study examines the fusogenicity and neutralization sensitivity of the SARS-CoV-2 AY.4.2 sublineage compared to the Delta variant, finding similar spike function but reduced neutralization sensitivity to certain antibodies and vaccines.

bioRxiv · Jan 7, 2022Microbiology

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

D. Planas, N. Saunders, P. Maes, F. G. Benhassine, C. Planchais, F. Porrot, I. Staropoli, F. Lemoine, H. Pere, D. Veyer, J. Puech, J. Rodary, W. H. Bolland, J. Buchrieser, G. Baele, , O. Schwartz

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

bioRxiv · Dec 14, 2021Immunology

SARS-CoV-2 Alpha, Beta and Delta variants display enhanced Spike-mediated Syncytia Formation

M. M. Rajah, M. Hubert, E. Bishop, N. Saunders, R. Robinot, L. Grzelak, D. Planas, J. Dufloo, S. Gellenoncourt, A. Bongers, M. Zivaljic, C. Planchais, F. Guivel-Benhassine, F. Porrot, H. Mouquet, , O. Schwartz

This study compares syncytia formation by SARS-CoV-2 Alpha, Beta, and Delta variants to D614G, finding enhanced fusogenicity and differential effects of mutations on ACE2 binding and antibody escape.

bioRxiv · Jun 11, 2021Microbiology

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, , O. Schwartz

This study shows that the SARS-CoV-2 B.1.617.2 variant is less sensitive to monoclonal antibodies and sera from convalescent and vaccinated individuals compared to other variants.

bioRxiv · May 26, 2021 · PreprintMicrobiology

Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen

A. Mac Kain, G. Maarifi, S.-M. Aicher, N. Arhel, A. Baidaliuk, S. Munier, F. Donati, T. Vallet, Q. D. Tran, A. Hardy, M. Chazal, F. Porrot, M. Ohainle, J. Carlson-Stevermer, J. Oki, , F. Roesch

The paper identifies DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen, showing it limits viral replication independently of SUMOylation.

bioRxiv · May 6, 2021Microbiology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

D. Planas, T. Bruel, L. Grzelak, F. Guivel-Benhassine, I. Staropoli, F. Porrot, C. Planchais, J. Buchrieser, M. M. Rajah, E. Bishop, M. Albert, F. Donati, S. Behillil, V. Enouf, M. Marianne, , O. Schwartz

This study assesses the neutralization sensitivity of SARS-CoV-2 B.1.1.7 and B.1.351 variants compared to D614G using sera and nasal swabs, finding reduced efficacy against B.1.351 in some convalescent and vaccinated individuals.

bioRxiv · Feb 12, 2021 · PreprintImmunology

Syncytia formation by SARS-CoV-2 infected cells

J. Buchrieser, J. Dufloo, M. Hubert, B. Monel, D. Planas, M. M. Rajah, C. Planchais, F. Porrot, F. Guivel-Benhassine, S. van der Werf, N. Casartelli, H. Mouquet, T. Bruel, O. Schwartz

This study shows SARS-CoV-2 infected cells form syncytia via Spike protein-mediated fusion, regulated by IFITMs and TMPRSS2.

The EMBO Journal · Nov 4, 2020Peer-reviewedMicrobiology